PAREXEL's Bio/pharmaceutical R & D Statistical SourcebookPAREXEL International Corporation, 2006 - Drugs |
From inside the book
88 pages matching clinical trials in this book
Page xi
Page xiii
Where's the rest of this book?
Results 1-3 of 88
Common terms and phrases
active Amgen analysis Anti-Infective approval phase approved drug AstraZeneca average billion Biogen Idec Biopharmaceutical biotech biotechnology blockbuster Bristol-Myers Squibb cancer Cardiovascular CBER CDER clinical development clinical phase clinical research clinical trials Cohort compounds CRO usage database disease Disorders Division Drug Development drugs approved enrollment estimates Europe fast track FDA First Action FDA Second Action firms Genentech GlaxoSmithKline global IMS Health in-licensing increase IND filing investment Japan late-stage launch Lehman Brothers Lilly Mean Clinical Median medicines MedImmune Merck NCES NDA Approval NDA Review new-engine NME approvals Novartis oncology Orphan Drug patients percent period Pfizer pharma companies pharmaceutical companies pharmaceutical industry Pharmaceutical R&D Pharmaprojects Phase IIb preclinical Priority projects R&D expenditure R&D spending regulatory Roche Sanofi-Aventis Schering-Plough Source Sponsor Response Study of Drug submission Success Rates Costs/Complexity survey targets therapeutic areas Therapeutic Category Tufts Center Tufts CSDD vaccines worldwide Wyeth